Randomized Treatment Interruption of Natalizumab.

Trial Profile

Randomized Treatment Interruption of Natalizumab.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Natalizumab (Primary) ; Glatiramer acetate; Interferon beta-1a; Methylprednisolone
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms RESTORE
  • Sponsors Biogen
  • Most Recent Events

    • 15 Sep 2017 Results assessing reversibility of natalizumab-mediated changes in pharmacokinetics/pharmacodynamics using patient data from AFFIRM and RESTORE trials published in the Neurology
    • 17 Sep 2016 Results of this and other four trials assessing relationship of natalizumab exposure and MRI response presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 28 Mar 2014 Results published in the Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top